Advertisement

Topics

Hutchison China MediTech (Chi-Med) Initiates A Phase I/II Clinical Trial Of Novel FGFR Inhibitor HMPL-453 In China

20:00 EDT 21 Jun 2017 | BioSpace

  Life Sciences Jobs   ...

Original Article: Hutchison China MediTech (Chi-Med) Initiates A Phase I/II Clinical Trial Of Novel FGFR Inhibitor HMPL-453 In China

NEXT ARTICLE

More From BioPortfolio on "Hutchison China MediTech (Chi-Med) Initiates A Phase I/II Clinical Trial Of Novel FGFR Inhibitor HMPL-453 In China"

Advertisement
Quick Search
Advertisement
Advertisement